Fierce Biotech1 min read
saveCoherus shrinks headcount 30% to narrow focus of cancer combo
Coherus Oncology is once again laying off 30% of its workforce as the biopharma narrows the focus of its CCR8-targeting antibody on esophageal cancer.
Coherus Oncology is once again laying off 30% of its workforce as the biopharma narrows the focus of its CCR8-targeting antibody on esophageal cancer.
comments(0)
5-min edit window · permanent after that